Targeting the p53/xCT/GSH Axis with PRIMA-1Met Combined with Sulfasalazine Shows Therapeutic Potential in Chronic Lymphocytic Leukemia. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.